German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.
Sproll will remain with the company on a part-time basis as a special advisor to chief executive officer Dr Simon Moroney, however Dr Enzelberger, who joined MorphySys in 2002, has served as its interim CSO since April this year.
Dr Enzelberger has served in various capacities at MorphoSys including senior vice president, discovery, alliances and technologies, taking responsibility for the drug discovery activities for proprietary and partnered programmes.
Dr Gerald Moller, supervisory board chairman, MorphoSys, said: “Dr Enzelberger is the perfect person to take over the CSO role at MorphoSys on a permanent basis.
“Drawing on his vast scientific expertise and experience in the management of antibody technology, research and discovery, he will continue to drive the group’s early-stage research activities with the goal of fuelling the company’s R&D pipeline with novel drug candidates in oncology and immunology.”